The role of bronchoscopy in patients with SARS-CoV-2 pneumonia

Marisol Arenas-De Larriva[1], Roberto Martín-DeLeon [2], Blanca Urrutia Royo[3], Iker Fernández-Navamuel[4], Andrés Gimenez Velando[4], Laura Nuñez García[4], Carmen Centeno Clemente[5], Felipe Andreo García [5], Albert Rafecas Codern[6], Carmen Fernández-Arias[6], Virginia Pajares Ruiz[6], Alfons Torrego Fernández[6], Olga Rajas[7], Gorane Iturricastillo[8], Ricardo Garcia Lujan[9], Lorena Comeche Casanova[10], Albert Sánchez-Font[11], Ricardo Aguilar-Colindres[12], Roberto Larrosa-Barrero[13], Ruth García García[14], Rosa Cordovilla[14], Ana Núñez-Ares[15], Andrés Briones-Gómez[16], Enrique Cases Viedma[16], José Franco[17], Javier Cosano Povedano[18], Manuel Luis Rodríguez-Perálvarez [19], Jose Joaquin Cebrian Gallardo[20], Manuel Nuñez Delgado[21], María Pavón-Masa[22], Maria del Mar Valdivia Salas[23] and Javier Flandes [24]

[1]Dept of Bronchoscopy and Interventional Pulmonology, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain. [2]Dept of Pulmonology, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain. [3]Pulmonary Dept, Thorax Clinic Institute, Hospital Universitari Germans Trias i Pujol, Badalona, Spain. [4]Bronchoscopy and Interventional Pulmonology Unit, Pulmonology Dept, Hospital Fundacion Jimenez Diaz, ISS-FJD, CIBERES, Madrid, Spain. [5]Interventional Pulmonology Unit, Pulmonary Dept, Thorax Clinic Institute, Hospital Universitari Germans Trias i Pujol, UAB, IGTP, Badalona, Spain. [6]Respiratory Dept, Hospital Santa Creu i Sant Pau, Barcelona, Spain. [7]Interventional Pulmonology Unit, Pulmonology Dept, Hospital Universitario de la Princesa, Instituto de Investigación Princesa, Madrid, Spain. [8]Pulmonology Dept, Hospital Universitario de la Princesa, Instituto de Investigación Princesa, Madrid, Spain. [9]Dept of Interventional Pulmonology, Hospital Universitario 12 Octubre and Hospital Univesitario Quirónsalud Madrid, Madrid, Spain. [10]Dept of Pulmonology, Hospital Universitario Quirónsalud Madrid, Madrid, Spain. [11]Pulmonology Dept, Hospital del Mar, CIBERES, UAB, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain. [12]Pulmonology Dept, Hospital del Mar, CIBERES, Barcelona, Spain. [13]Pulmonary Dept, Hospital Universitario Clínico San Carlos, Madrid, Spain. [14]Interventional Pulmonology Unit, Pulmonary Dept, Salamanca University Hospital, Salamanca, Spain. [15]Interventional Pulmonology Unit, Pulmonary Dept, Albacete, Spain. [16]Interventional Pulmonology Unit, Pulmonary Dept, Hospital Universitario y Politécnico La Fe, Valencia, Spain. [17]Pneumology Service, Clinic University Hospital, INCLIVA Health Research Institute, Valencia, Spain. [18]Bronchoscopy and Interventional Pulmonology Unit, Pulmonology Dept, Hospital Universitario Reina Sofía, IMIBIC, Córdoba, Spain. [19]Maimónides Institute of Biomedical Research of Córdoba (IMIBIC), CIBERehd, Córdoba, Spain. [20]Dept of Pulmonology, Agencia sanitaria Costa del Sol, Marbella, Spain. [21]Dept of Bronchoscopy and Interventional Pulmonology, Hospital Álvaro Cunqueiro, CHUVI, Vigo, Spain. [22]Dept of Interventional Pulmonology, Hospital Universitario Virgen Macarena, Seville, Spain. [23]Dept of Interventional Pulmonology, Hospital Universitario Santa Lucía, Cartagena, Spain. [24]Bronchoscopy and Interventional Pulmonology Unit, Pulmonology Dept, Hospital Fundación Jimenez Diaz, ISS-FJD, CIBERES, Madrid, Spain.

Corresponding author: Marisol Arenas-De Larriva (arlam23@hotmail.com)

Abstract

Background The role of bronchoscopy in coronavirus disease 2019 (COVID-19) is a matter of debate.

Patients and methods This observational multicentre study aimed to analyse the prognostic impact of bronchoscopic findings in a consecutive cohort of patients with suspected or confirmed COVID-19. Patients were enrolled at 17 hospitals from February to June 2020. Predictors of in-hospital mortality were assessed by multivariate logistic regression.

Results A total of 1027 bronchoscopies were performed in 515 patients (age 61.5±11.2 years; 73% men), stratified into a clinical suspicion cohort (n=30) and a COVID-19 confirmed cohort (n=485). In the clinical suspicion cohort, the diagnostic yield was 36.7%. In the COVID-19 confirmed cohort, bronchoscopies were predominantly performed in the intensive care unit (n=961; 96.4%) and major indications were: difficult mechanical ventilation (43.7%), mucus plugs (39%) and persistence of radiological infiltrates (23.4%).

147 bronchoscopies were performed to rule out superinfection, and diagnostic yield was 42.9%. There were abnormalities in 91.6% of bronchoscopies, the most frequent being mucus secretions (82.4%), haematic secretions (17.7%), mucus plugs (17.6%), and diffuse mucosal hyperaemia (11.4%). The independent predictors of in-hospital mortality were: older age (OR 1.06; p<0.001), mucus plugs as indication for bronchoscopy (OR 1.60; p=0.041), absence of mucosal hyperaemia (OR 0.49; p=0.041) and the presence of haematic secretions (OR 1.79; p=0.032).

Conclusion Bronchoscopy may be indicated in carefully selected patients with COVID-19 to rule out superinfection and solve complications related to mechanical ventilation. The presence of haematic secretions in the distal bronchial tract may be considered a poor prognostic feature in COVID-19.

Introduction

The novel coronavirus disease 2019 (COVID-19), which is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), originated in Wuhan in the province of Hubei, China, in December 2019 [1]. COVID-19 rapidly spread to other countries driven by an increased prevalence of asymptomatic carriers and by the airborne transmission of SARS-CoV-2 [2]. In March 2020, COVID-19 was declared a pandemic by the World Health Organization, and since then has challenged healthcare systems worldwide, making the need to optimise clinical pathways and resource utilisation mandatory.

The role of bronchoscopy in COVID-19 is a matter of debate. Among patients with clinical suspicion of COVID-19 with negative nasopharyngeal swab specimen results by real-time PCR with reverse transcription (RT-PCR), bronchoscopy could provide increased sensitivity by obtaining samples from the lower respiratory tract [3]. In patients with severe COVID-19, mainly admitted to the intensive care unit (ICU), bronchoscopy may be required to manage complications such as atelectasis or haemoptysis, to solve issues with mechanical ventilation, and to rule out superinfection. However, bronchoscopy in COVID-19 is not without risks, including disease transmission to healthcare staff. Although some scientific societies have issued guidelines in order to reduce heterogeneity in clinical practice [4], the supporting scientific background is scarce and is mainly composed by short series [5–7].

The main end-point of the present nationwide study was to evaluate the impact of endoscopic findings on outcomes among patients with COVID-19. Secondary outcomes were: 1) to describe the indications for bronchoscopy and procedures; 2) to analyse the diagnostic yield of bronchoscopy in patients with suspected SARS-CoV-2 pneumonia.

Materials and methods

The "COronavirus & BRonchoscopy in Spain (COBRE)" project is an ambispective multicentre study, which was launched during the first epidemic wave of COVID-19 in Spain. The study was performed according to the principles of the Declaration of Helsinki and aligning with the European Union regulation 2016/679. The study was approved by the Research Ethics Committee of the Hospital Universitario Reina Sofía, Córdoba, Spain (PI 2020/4680).

Study population

Patients were enrolled at 17 secondary and tertiary hospitals in Spain. The recruitment period ranged from February 20, 2020, when the national authorities informed about community transmission of SARS-CoV-2, until June 30, 2020, when there was an official declaration of controlled community transmission. Patients admitted to the hospital because of suspected or confirmed COVID-19 who required a bronchoscopy were consecutively included and stratified into two study cohorts:

1. Clinical suspicion cohort: patients with clinical and radiological features of COVID-19 or positive IgM antibody testing, but without confirmation by RT–PCR in two consecutive nasopharyngeal swab specimens, who underwent bronchoscopy for diagnostic purposes.
2. RT-PCR confirmed cohort: patients with SARS-CoV-2 pneumonia confirmed by RT-PCR of nasopharyngeal swab specimens who required a bronchoscopy.

The exclusion criteria for both cohorts were as follows: patients younger than 18 years old; bronchoscopy performed after virological resolution (confirmed by two consecutive RT-PCR negative tests); interval between COVID-19 confirmation and endoscopic examination longer than 30 days.

Identification of study candidates, data extraction and outcomes

Potential study candidates were screened among patients admitted to the hospital with suspected or confirmed COVID-19. Those patients with compatible clinical symptoms and typical radiological findings [8] with two negative RT-PCR of nasopharyngeal swab specimens could undergo bronchoscopy to obtain a lower respiratory tract specimen and they formed the clinical suspicion cohort. Patients with previous

positive RT-PCR of SARS-CoV-2 in nasopharyngeal swab specimens who underwent bronchoscopy to rule out superinfection or for therapeutic purposes formed the RT-PCR-confirmed cohort.

Data were recorded in an anonymised electronic datasheet using the REDCap (Research Electronic Data Capture) platform [9]. Study investigators received online training at baseline to homogenise the data collection, and they were granted access with a unique username/password. All clinical information was extracted from reliable electronic medical data sources. Demographic characteristics and comorbidities (graded with the Charlson comorbidity index as absent if 0–1, mild if 2 or severe if ⩾3 [10]), clinical symptoms and diagnostic tests of COVID-19 were recorded. Blood tests and radiological features were considered within the 48 h prior to bronchoscopy. Imaging findings obtained in chest computed tomography (CT) were reported according to the COVID-RADS classification as typical, fairly typical, atypical or normal [11]. Bronchoscopic findings and procedures were also registered. Patients were followed until hospital discharge or death. The main outcome evaluated was in-hospital mortality at 90 days after bronchoscopy.

Sample size calculation

The sample size was calculated using EPIDAT version 4.2 (Xunta de Galicia, Spain). The following assumptions were made to study a theoretical relationship between endoscopic findings and outcomes:

- The prevalence of an endoscopic feature indicating poor prognosis: 20%.
- In-hospital mortality in patients showing an endoscopic feature indicating poor prognosis: 40% (obtained from the upper range of mortality reported in previous series of critically ill patients [12, 13]).
- In-hospital mortality in patients without an endoscopic feature indicating poor prognosis: 25% (obtained from the lower range of mortality reported in previous series of critically ill patients [12, 13]).
- Statistical power: 80%
- α error: 5%
- Incomplete or unavailable data: 5%

Under these premises, the minimum sample size required was 483 patients with RT-PCR-confirmed COVID-19. The study finally comprised 515 patients, including 488 RT-PCR-confirmed cases.

Statistical analysis

Categorical variables were described as frequency tables and percentages. Continuous variables were described using mean and standard deviation, except for those with an asymmetric distribution, in which median and interquartile range (IQR) were used. To identify clinical, radiological and endoscopic features associated with in-hospital mortality at 90 days, the first bronchoscopy performed in each patient with RT-PCR-confirmed COVID-19 was considered. Univariate and multivariate logistic regression was used. Variables with $p<0.30$ in the univariate analysis were entered the initial multivariate model. Endoscopic features with a prevalence ⩾5% were also included in the initial multivariate model irrespective of their univariate p-value. Nonsignificant covariates were removed in a backward stepwise process. All possible interactions were tested. Clinically meaningful variables were also kept in the final model even if they did not reach statistical significance. Kaplan–Meier curves were used for survival analysis, being patients censored at hospital discharge or on October 30, 2020. The statistical analysis was performed using SPSS version 22.0 (IBM Corp, Armonk, NY, USA). Every hypothesis tested was two-tailed and considered significant if $p<0.05$.

Results
Description of the study population

A total of 1027 bronchoscopies were performed in 515 patients (average age 61.5±11.2; 73% men). The clinical suspicion cohort comprised 30 patients (5.8%), while the remaining 485 patients (94.2%) were RT-PCR-confirmed COVID-19, including 86 patients who underwent 147 bronchoscopies to rule out superinfection and 399 patients who required 850 therapeutic bronchoscopies. The clinical characteristics of both cohorts are summarised in table 1. Severe comorbidity defined as a Charlson score ⩾3 was more frequent in the clinical suspicion cohort (33.3%) as compared with the RT-PCR-confirmed cohort (10.1%) ($p<0.001$). The clinical presentation was almost indistinguishable in both cohorts, except for an increased prevalence of cough and myalgias in the RT-PCR-confirmed cohort (74.2% *versus* 50%, $p=0.004$; and 32.2% *versus* 13.3%, $p=0.031$, respectively). In the radiographs, bilateral infiltrates predominated in the RT-PCR-confirmed cohort (83.5% *versus* 60%; $p<0.001$). Admission to the ICU was required in 95.2% of patients in the RT-PCR-confirmed cohort as compared with 26.7% of patients in the clinical suspicion cohort ($p<0.001$).

TABLE 1 Clinical characteristics of 515 patients admitted to the hospital with suspected or confirmed COVID-19 who required a bronchoscopy

Variable	Clinical suspicion cohort (n=30)	RT-PCR-confirmed cohort (n=485)	p-value
Age, mean±SD	59.2±15.5	61.7±10.9	0.390
Women	36.7% (11)	26.4% (128)	0.219
Previous medical history			
Diabetes	20% (6)	22.5% (109)	0.752
Hypertension	36.7% (11)	47.6% (231)	0.243
Cardiovascular	13.3% (4)	10.9% (53)	0.684
Bronchopulmonary	23.3% (7)	14% (68)	0.161
Neoplasms	30% (9)	9.3% (45)	0.002
Charlson comorbidity index			<0.001
0–1	53.3% (16)	77.3% (375)	
2	13.3% (4)	12.6% (61)	
⩾3	33.3% (10)	10.1% (49)	
Tobacco consumption			0.046
Current smokers	17.9% (5)	6.2% (29)	
Past smokers	17.9% (5)	28% (130)	
Nonsmokers	64.2% (18)	65.8% (306)	
Lifetime tobacco consumption[#], pack-years	21.5 (11.5–46.2)	30 (15–40)	0.988
Immunosuppression			
HIV	3.3% (1)	0.8% (4)	0.174
Chemotherapy	16.7% (5)	1% (5)	<0.001
Monoclonal antibodies	3.3% (1)	1% (5)	0.304
Calcineurin inhibitors	10% (3)	2.1% (10)	0.034
Antimetabolites	6.7% (2)	2.1% (10)	0.151
Corticosteroids	0% (0)	2.9% (14)	1
Clinical presentation of COVID-19			
Fever	76.7% (23)	83.1% (403)	0.366
Dyspnoea	56.7% (17)	67.4% (327)	0.225
Cough	50% (15)	74.2% (360)	0.004
Gastrointestinal symptoms	16.7% (5)	23.1% (112)	0.415
Myalgias	13.3% (4)	32.2% (156)	0.031
Anosmia/ageusia	0 (0%)	6.6% (32)	0.245
Laboratory parameters			
P_{aO_2}/F_{IO_2} ratio[¶]	270 (196–288)	160 (118–216)	0.038
S_{aO_2}/F_{IO_2} ratio[+]	329 (235–387)	184 (132–239)	<0.001
Lymphocyte count·μL^{-1}	890 (490–1540)	700 (540–1000)	0.115
D dimer ng·mL^{-1}	1113 (577–2170)	843 (492–1605)	0.545
Lactate dehydrogenase U·L^{-1}	304 (239–507)	450 (340–625)	0.049
Ferritin ng·mL^{-1}	589 (359–1356)	1275 (648–2299)	0.107
C-reactive protein mg·L^{-1}	36 (12–166)	22 (11–81)	0.438
Interleukin-6 pg·mL^{-1}	46 (5–149)	65 (23–130)	0.546
Chest radiograph abnormalities			<0.001
Normal	0% (0)	0.4% (2)	
Unilateral interstitial	23.3% (7)	1.6% (8)	
Bilateral interstitial	43.3% (13)	36.7% (178)	
Unilateral consolidation	6.7% (2)	2.9% (14)	
Bilateral consolidation	16.7% (5)	46.8% (227)	
Others	10% (3)	11.5% (56)	
COVID-19-specific therapy			
Azithromycin	0% (0)	50.4% (242)	<0.001
Hydroxychloroquine	3.3% (1)	75.4% (362)	<0.001
Lopinavir/ritonavir	3.3% (1)	54% (259)	<0.001
Remdesivir	0% (0)	5% (24)	0.386
Interferon-β	3.3% (1)	15.2% (73)	0.104
Anakinra	0% (0)	3.8% (18)	0.616
Tocilizumab	3.3% (1)	49.2% (236)	<0.001
Antibiotics	3.3% (1)	31.7% (152)	<0.001

Continued

TABLE 1 Continued			
Variable	Clinical suspicion cohort (n=30)	RT-PCR-confirmed cohort (n=485)	p-value
Corticosteroids	3.3% (1)	70.4% (338)	<0.001
Length of hospital stay, days	18 (8–28)	38 (22–61)	0.007
Admission to intensive care unit	26.7% (8)	95.2% (456)	<0.001
In-hospital mortality	20% (6)	33.6% (163)	0.123

Data are presented as % (n) or median (interquartile range), unless otherwise stated. P_{aO_2}: arterial oxygen tension; F_{IO_2}: inspiratory oxygen fraction; S_{aO_2}: arterial oxygen saturation. [#]: only accounted for current/past smokers; [¶]: P_{aO_2}/F_{IO_2} was available in 298 patients; [+]: S_{aO_2}/F_{IO_2} was available in 140 patients who did not have P_{aO_2}/F_{IO_2}.

Clinical suspicion cohort

Bronchoscopies were performed in the bronchoscopy room (50%), ICU (26.7%), respiratory ward (20%) or in the operating room (3.3%). Disposable bronchoscopes were used in 18 procedures (60%) and the preferred access was *via* nasal (63.3%). Lower respiratory tract specimens obtained were: bronchial aspiration (BAS) (31.6%), bronchoalveolar lavage (BAL) (10.5%), bronchial washing (10.5%) and a combination of BAS and BAL (47.4%). RT-PCR was positive for SARS-CoV-2 in 11 patients (36.7%). Of note, none of the patients undergoing BAS alone had a positive RT-PCR, while the diagnostic yield of the remaining specimens ranged from 40% to 60%. Among 19 patients without confirmation of SARS-CoV-2, 5 patients (26.3%) had an alternative diagnosis (*Cytomegalovirus*, *Pneumocystis*, *Aspergillus* and/or *Staphylococcus*), and 14 patients had no proven microbiological agent in the lower respiratory tract specimens. None of these patients had a subsequent positive test for COVID-19. Patients with and without SARS-CoV-2 confirmation did not show statistical differences regarding age (p=0.90), sex distribution (p=0.70), smoking history (p=0.18) and Charlson comorbidity index (p=0.47). Fever, cough, dyspnoea and myalgias were distributed homogeneously in both groups (p=0.61, p=0.70, p=0.13, and p=0.61, respectively). Patients with a SARS-CoV-2-positive RT-PCR were characterised by an increased prevalence of gastrointestinal symptoms (36.4% *versus* 5.3%; p=0.047). Laboratory parameters including lymphocyte count, D dimer, lactate dehydrogenase, ferritin, C-reactive protein and interleukin-6 were similar in the RT-PCR-positive and -negative groups (data not shown). The chest radiographs showed interstitial bilateral infiltrates in 63.6% of patients from the SARS-CoV-2-positive group as compared with 31.6% of patients without COVID-19 confirmation (p=0.09). A chest CT was performed in 14 patients within 48 h prior to bronchoscopy (6 patients with subsequent positive RT-PCR and eight patients with subsequent negative RT-PCR). There was a typical or fairly typical radiological pattern of COVID-19 in the vast majority of patients (78.6%), without statistical differences between patients with subsequent positive and negative RT-PCR results. There were endoscopic abnormalities in 63.6% of patients with positive COVID-19 RT-PCR *versus* 36.8% of patients with negative COVID-19 RT-PCR results (p=0.16). The most frequent bronchoscopic findings were thick mucus secretion (n=9), fluid mucus secretion (n=4) and diffuse mucosal hyperaemia (n=3). Admission to the ICU was required in 18.2% of patients with a positive RT-PCR and in 31.6% of patients with a negative RT-PCR (p=0.67). The in-hospital mortality was 18.2% in patients with a SARS-CoV-2-positive RT-PCR and 21.1% in patients with negative RT-PCR (log-rank p=0.47).

RT-PCR-confirmed cohort

The RT-PCR-confirmed cohort included 485 hospitalised patients who underwent 997 bronchoscopies (range 1–16 procedures per patient). The number of healthcare professionals involved in each procedure ranged from 1 to 5. Bronchoscopies were performed predominantly in the ICU (n=961; 96.4%), followed by the COVID-19 ward (n=18; 1.8%), endoscopy room (n=15; 1.5%) and operating room (n=3; 0.3%). The vast majority of procedures were performed in rooms without negative pressure (90.7%) and using disposable bronchoscopes (94.5%). Regarding ventilatory support, most bronchoscopies were performed with patients under invasive mechanical ventilation (93.2%) and in 66 cases (6.6%) under extracorporeal membrane oxygenation. The predominant accesses were orotracheal tube (61%) and tracheostomy (35.2%). The patient was in prone position in 55 bronchoscopies (5.5%). The ratio of partial pressure arterial oxygen and fraction of inspired oxygen was 171.9±80.6. Bronchoscopies were indicated to rule out superinfection (14.7%) or for therapeutic purposes (85.3%). Therapeutic indications and endoscopic findings are summarised in table 2. Major indications for bronchoscopy were complications associated with mechanical ventilation (50%), mucus plugs/atelectasis (46%), persistence or progression of radiological infiltrates (33.4%) and haemoptysis (6%). There were endoscopic abnormalities in 91.6%, the

TABLE 2 Therapeutic indications and findings in 997 bronchoscopies performed in 485 hospitalised patients with RT-PCR-confirmed SARS-CoV-2 pneumonia

Indications	
Atelectasis	7% (70)
Mucus plugs	39% (389)
Haemoptysis	6% (60)
Radiological progression	10% (100)
Persistence of radiological infiltrates	23.4% (233)
Difficult mechanical ventilation	43.7% (436)
Impossible weaning from mechanical ventilation	6.3% (63)
Findings	
Normal	8.4% (84)
Diffuse mucosal hyperaemia	11.4% (114)
Thick mucus secretion	59.9% (597)
Fluid mucus secretion	22.5% (224)
Mucus plugs	17.6% (175)
Haematic secretions	17.7% (176)
Intrabronchial clots	6% (60)
Location of mucus plugs (n=175)	
Trachea	24% (42)
Main right bronchus	31.4% (55)
Main left bronchus	33.5% (59)
Right superior bronchus	18.3% (32)
Right middle bronchus	24% (42)
Right inferior bronchus	45.1% (79)
Left superior bronchus	16% (28)
Left inferior bronchus	36.6% (64)
Location of intrabronchial clots (n=60)	
Trachea	31.7% (19)
Main right bronchus	55% (33)
Main left bronchus	41.7% (25)
Right superior bronchus	15% (9)
Right middle bronchus	21.7% (13)
Right inferior bronchus	40% (24)
Left superior bronchus	10% (6)
Left inferior bronchus	20% (12)
Therapy	
Aspiration	82.3% (821)
Removal with grasp forceps	1.4% (14)
Cannula placement	0.3% (3)
Bronchial occlusion	0.2% (2)
Cryotherapy	0.1% (1)
Endobronchial selective intubation	0.1% (1)
Intrabronchial drugs	
Saline solution	60.2% (600)
Mesna	5.1% (51)
Hypertonic solution	14.5% (145)
N-acetylcysteine	6% (60)
Hyaluronic acid (+hypertonic solution)	6.5% (65)
Others	0.9% (9)
Samples	
Bronchial aspiration	43% (429)
Combined bronchial aspiration and bronchoalveolar lavage	24.3% (242)
Bronchoalveolar lavage	5.8% (58)
Bronchial washing	11% (110)
Microbiological agents	
Bacteria	27.2% (271)
Fungi	12.8% (128)
Virus	3.6% (36)

Data are presented as % (n).

most frequent being mucus secretions (82.4%), mucus plugs (17.6%), haematic secretions/clots (23.7%) and diffuse mucosal hyperaemia (11.4%) (figure 1). The most frequent therapy consisted in atelectasis resolution or mucus aspiration (82.3%). Among 147 bronchoscopies performed to rule out superinfection, the microbiological samples were obtained from: BAS (11.6%), BAL (10.9%), bronchial washing (52.5%), and BAS in combination with BAL (21.7%). The diagnostic yield was 42.9%, including 71 microbiological isolations which are detailed as supplementary material.

Impact of endoscopic findings on outcomes

All patients with RT-PCR-confirmed COVID-19, either in nasopharyngeal swab or in lower respiratory tract specimens, were included to evaluate clinical, radiological and endoscopic features associated with mortality (n=496). Univariate and multivariate logistic regression analyses to predict in-hospital mortality at 90 days are shown in table 3. The independent predictors of in-hospital mortality were: older age (OR 1.06, 95% CI 1.03–1.08; p<0.001), mucus plugs as indication for bronchoscopy (OR 1.60, 95% CI 1.02–2.53; p=0.041), absence of diffuse mucosal hyperaemia (OR 0.49, 95% CI 0.25–0.97; p=0.041), and the presence of haematic secretions (OR 1.79, 95% CI 1.05–3.05; p=0.032) in the distal bronchial tract. A Charlson score ⩾3 was kept in the final model as clinically relevant information. The interval from hospital admission to bronchoscopy behaved as a confounding factor and was controlled in the final model. In the survival analysis, the presence of haematic secretions in the distal bronchial tract was the only endoscopic finding associated with mortality: 53.2% versus 35.7% at 60 days and 61% versus 39.5% at 90 days post-bronchoscopy (log-rank p=0.038) (figure 2).

Discussion

The present study was carried out in the largest cohort published to date and provides key evidence regarding potential indications for bronchoscopy in patients with suspected or confirmed COVID-19, both for diagnostic or therapeutic purposes. Interestingly, some bronchoscopic findings were independently associated with in-hospital mortality after controlling for potential confounders. This information could be used to refine healthcare pathways and to reduce heterogeneity in clinical practice, in order to improve outcomes in patients with severe COVID-19.

The diagnosis of SARS-CoV-2 pneumonia is challenging when RT-PCR is negative in conventional nasopharyngeal swabs. Previous studies have suggested that lower respiratory tract specimens could increase sensitivity and allow diagnosis in patients with reduced viral load [3], while others recommend avoiding bronchoscopy for diagnostic purposes [14]. The selection of candidates for diagnostic bronchoscopy is paramount as this is an invasive procedure, not without risk of complications, and there is also a potential risk of spreading the infection to the medical staff due to the aerosols generated therein [15]. Only patients with high clinical suspicion of COVID-19 and typical radiological findings who test negative in two consecutive nasopharyngeal swabs may be considered for diagnostic bronchoscopy.

FIGURE 1 Most representative bronchoscopic findings in patients with RT-PCR-confirmed COVID-19. a) Haematic secretions (arrows). b) Mucus secretions. Pictures were obtained using disposable bronchoscopes.

TABLE 3 Clinical, radiological and endoscopic predictors of in-hospital mortality at 90 days among patients with RT-PCR-confirmed COVID-19 admitted to the hospital who required a first bronchoscopy (n=496)

Variables	Univariate analysis		Multivariate analysis (initial model)		Multivariate analysis (final model)	
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
Age	1.05 (1.03–1.08)	<0.001	1.05 (1.03–1.08)	<0.001	1.06 (1.03–1.08)	<0.001
Sex, women	1.14 (0.74–1.74)	0.551				
Medical history						
Diabetes	0.96 (0.62–1.50)	0.872				
Hypertension	1.22 (0.84–1.77)	0.292	0.93 (0.59–1.47)	0.768		
Cardiovascular	0.73 (0.39–1.37)	0.333				
Bronchopulmonary	1.08 (0.64–1.83)	0.767				
Neoplasms	0.77 (0.40–1.47)	0.427				
Charlson comorbidity index ⩾3	1.15 (0.63–2.09)	0.644	1.25 (0.62–2.53)	0.526	1.07 (0.56–2.04)	0.834
Current/past smoking	1.18 (0.79–1.76)	0.403				
Interval hospital admission to FBC	0.99 (0.98–1.00)	0.053	0.99 (0.98–1.00)	0.163	0.99 (0.98–1.00)	0.076
Clinical presentation						
Fever	0.84 (0.51–1.37)	0.491				
Dyspnoea	1.26 (0.84–1.88)	0.263	1.44 (0.88–2.33)	0.144		
Cough	0.82 (0.54–1.25)	0.361				
Gastrointestinal	1.05 (0.67–1.62)	0.832				
Myalgias	1.08 (0.72–1.60)	0.713				
Laboratory parameters						
Lymphocyte count	1.00 (0.99–1.00)	0.272	1.00 (1.00–1.00)	0.901		
D dimer	1.00 (1.00–1.00)	0.068	1.00 (1.00–1.00)	0.123		
Lactate dehydrogenase	1.00 (1.00–1.00)	0.543				
Ferritin	1.00 (1.00–1.00)	0.318				
C-reactive protein	1.00 (0.99–1.00)	0.151	1.00 (0.99–1.00)	0.206		
Interleukin-6	1.00 (1.00–1.00)	0.498				
Radiograph, bilateral involvement	1.11 (0.67–1.84)	0.681				
Indications for bronchoscopy						
Atelectasis	1.02 (0.53–1.96)	0.951				
Mucus plugs	1.42 (0.94–2.14)	0.092	1.63 (0.97–2.73)	0.063	1.60 (1.02–2.53)	0.041
Haemoptysis	1.26 (0.60–2.67)	0.540				
Radiological	1.41 (0.91–2.21)	0.123				
Persistence/progression						
Difficult mechanical ventilation[#]	1.21 (0.83–1.75)	0.319				
Bronchoscopy findings						
Mucosal hyperaemia	0.81 (0.44–1.50)	0.506	0.45 (0.22–0.94)	0.035	0.49 (0.25–0.97)	0.041
Thick mucus	1.19 (0.82–1.73)	0.365	1.67 (0.99–2.80)	0.051		
Fluid mucus	0.96 (0.61–1.52)	0.964	1.42 (0.75–2.67)	0.281		
Mucus plugs	1.41 (0.89–2.26)	0.142	1.13 (0.63–2.06)	0.673		
Haematic secretions	1.78 (1.09–2.89)	0.020	1.98 (0.63–2.06)	0.028	1.79 (1.05–3.05)	0.032
Clots	1.59 (0.70–3.57)	0.266	1.87 (0.30–2.51)	0.793		

Univariate and multivariate logistic regression analyses were used. FBC: fibreoptic bronchoscopy. [#]: includes impossible weaning from mechanical ventilation.

The diagnostic yield of lower respiratory tract samples in the present study was 36.7% for SARS-CoV-2 (53% if alternative microbiological agents were considered), which was lower than in previous reports (55–71%) [3, 5]. This may be due to different selection criteria including the number of prior negative swabs and CT findings. In our study, patients with positive and negative results had a similar clinical presentation and laboratory findings, suggestive of high clinical suspicion of COVID-19 in this cohort. Gastrointestinal symptoms could identify a subgroup of candidates for diagnostic bronchoscopy. Another way to optimise the selection of candidates would be to avoid patients with atypical radiological findings [16]. According to our results, bilateral involvement in the chest radiography and typical or fairly typical findings in the CT as previously defined [11], may help to achieve better selection of patients, thus refining clinical pathways.

International scientific societies and expert panels have issued recommendations to safely perform bronchoscopy in patients with suspected or confirmed COVID-19 [17–20]. However, statements regarding the optimal approach to obtain microbiological samples are vague. This may explain the heterogeneity in

FIGURE 2 Kaplan–Meier curve showing the influence of haematic secretions in the distal bronchial tract on mortality in 496 patients with RT-PCR-confirmed COVID-19 admitted to the hospital.

clinical practice, as illustrated in the present study. According to our results, BAS alone should be avoided but other options including BAL, bronchial washing or BAL in combination with BAS, would be equally valid. In contrast, guidelines are broadly homogeneous regarding protocols to protect healthcare personnel [17, 20, 21]. In brief, bronchoscopies in patients with suspected or confirmed COVID-19 should be performed in negative-pressurised or in adequately ventilated rooms. The involved healthcare personnel may be experienced and reduced to the minimum (two or three people depending on the procedure). Disposable bronchoscopes are advised. Individual enhanced third-degree protection elements are required (protective glasses or face shield, FFP3 face masks, protective clothing, gloves, *etc.*). Unfortunately, some of these recommendations are difficult to implement in real clinical practice, particularly in secondary hospitals, which were overwhelmed during the peak of the pandemic. Negative-pressurised rooms are anecdotal in ICUs where most therapeutic endoscopies need to be performed. These structural deficiencies should be urgently amended by healthcare authorities to protect medical staff from COVID-19 transmission. In any case, the decision to perform (or not perform) a bronchoscopy in a patient with COVID-19 should be taken after a careful weighing of potential benefits against the potential risk of disease transmission to healthcare personnel.

Critically ill patients with COVID-19 usually require prolonged mechanical ventilation. Bronchoscopy may help to prevent, diagnose or resolve ventilator-related complications. This is the first multicentre study describing the indications and procedures in this setting. The presence of mucus plugs was the only indication independently associated with worse outcomes (60% increased mortality rates as compared with other indications), although it is tightly related to other indications such as atelectasis, superinfection and difficult mechanical ventilation. It is paramount to optimise ventilation to prevent excess secretions and to perform frequent aspirations through the endotracheal tube [20].

There are well established clinical, analytical and radiological predictors of poor outcomes in patients with COVID-19 including (but not limited to) older age, men, increased comorbidities, lymphopenia, increased D dimer and serum ferritin, and extent of pneumonia in the chest CT [22, 23]. This is the first study sufficiently powered to analyse the impact of bronchoscopic findings on outcomes among hospitalised patients with COVID-19. The presence of diffuse mucosal hyperaemia was associated with reduced

in-hospital mortality rates, as it is likely a typical feature of an earlier phase of COVID-19, indicating acute inflammation [24]. This situation may still be reversible with or without anti-inflammatory drugs such as corticosteroids [25]. However, the disappearance of this endoscopic sign under persistent respiratory insufficiency may indicate a poor prognosis. The presence of haematic secretions in the distal bronchial tract was an independent predictor of increased in-hospital mortality. In contrast to diffuse mucosal hyperaemia, haematic secretions could translate into irreversible damage of the capillaries and the interstitial/alveolar space, which characterises the most advanced and severe forms of COVID-19 [26–28]. Indeed, the presence of haematic secretions identified a subgroup of very sick patients (16%) with in-hospital mortality above 60%. Further studies focused on this subpopulation are needed to delineate more aggressive and life-saving therapies.

The present study is limited by its ambispective design which precluded a protocolised clinical management of the study population. Although laboratory and radiological assessment of patients with COVID-19 varied among different institutions, making it difficult to extract solid conclusions regarding these parameters, the study adequately captured the heterogeneity in real clinical practice. On the other hand, the number of patients in the clinical suspicion cohort was limited as this indication is uncommon and not accepted by some experts [14]. Finally, a potential relationship between ventilator-derived trauma and some bronchoscopic findings in critically ill patients could not be ruled out.

In conclusion, bronchoscopy is pivotal as part of the armamentarium against COVID-19. In carefully selected patients with clinical and radiological suspicion of SARS-CoV-2 pneumonia who test negative in nasopharyngeal swabs, a lower respiratory tract specimen may provide an acceptable diagnostic yield, also including the identification of alternative microbiological agents or superinfection. In critically ill patients with COVID-19, bronchoscopy allows removal of mucus plugs and intrabronchial clots, and the resolution of atelectasis, thereby improving mechanical ventilation. Finally, haematic secretions in the respiratory tract and absence of diffuse mucosal hyperaemia are poor prognostic features.

References

1 Huang C, Wang Y, Li X, *et al.* Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395: 497–506.

2 Fennelly KP. Particle sizes of infectious aerosols: implications for infection control. *Lancet Respir Med* 2020; 8: 914–924.

3 Wang W, Xu Y, Gao R, *et al.* Detection of SARS-CoV-2 in different types of clinical specimens. *JAMA* 2020; 323: 1843–1844.

4 Lentz RJ, Colt H. Summarizing societal guidelines regarding bronchoscopy during the COVID-19 pandemic. *Respirology* 2020; 25: 574–577.

5   Mondoni M, Sferrazza Papa GF, Rinaldo R, *et al.* Utility and safety of bronchoscopy during the SARS-CoV-2 outbreak in Italy: a retrospective, multicentre study. *Eur Respir J* 2020; 56: 2002767.

6   Torrego A, Pajares V, Fernandez-Arias C, *et al.* Bronchoscopy in patients with COVID-19 with invasive mechanical ventilation: a single-center experience. *Am J Respir Crit Care Med* 2020; 202: 284–287.

7   Chang SH, Jiang J, Kon ZN, *et al.* Safety and efficacy of bronchoscopy in critically ill patients with coronavirus disease 2019. *Chest* 2021; 159: 870–872.

8   Kanne JP, Bai H, Bernheim A, *et al.* COVID-19 Imaging: what we know now and what remains unknown. *Radiology* 2021; 299: 204522.

9   Harris PA, Taylor R, Minor BL, *et al.* The REDCap consortium: building an international community of software platform partners. *J Biomed Inform* 2019; 95: 103208.

10   Charlson ME, Pompei P, Ales KL, *et al.* A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis* 1987; 40: 373–383.

11   Salehi S, Abedi A, Balakrishnan S, *et al.* Coronavirus disease 2019 (COVID-19) imaging reporting and data system (COVID-RADS) and common lexicon: a proposal based on the imaging data of 37 studies. *Eur Radiol* 2020; 30: 4930–4942.

12   Grasselli G, Zangrillo A, Zanella A, *et al.* Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy region, Italy. *JAMA* 2020; 323: 1574–1581.

13   Bhatraju PK, Ghassemieh BJ, Nichols M, *et al.* COVID-19 in critically ill patients in the Seattle region - case series. *N Engl J Med* 2020; 382: 2012–2022.

14   Ora J, Puxeddu E, Cavalli F, *et al.* Does bronchoscopy help the diagnosis in COVID-19 infection? *Eur Respir J* 2020; 56: 2001619.

15   Jackson T, Deibert D, Wyatt G, *et al.* Classification of aerosol-generating procedures: a rapid systematic review. *BMJ Open Respir Res* 2020; 7: e000730.

16   Ai T, Yang Z, Hou H, *et al.* Correlation of chest CT and RT-PCR testing for coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. *Radiology* 2020; 296: E32–E40.

17   Wahidi MM, Shojaee S, Lamb CR, *et al.* The use of bronchoscopy during the coronavirus disease 2019 pandemic: CHEST/AABIP guideline and expert panel report. *Chest* 2020; 158: 1268–1281.

18   Luo F, Darwiche K, Singh S, *et al.* Performing bronchoscopy in times of the COVID-19 pandemic: practice statement from an international expert panel. *Respiration* 2020; 99: 417–422.

19   Steinfort DP, Herth FJF, Irving LB, *et al.* Safe performance of diagnostic bronchoscopy/EBUS during the SARS-CoV-2 pandemic. *Respirology* 2020; 25: 703–708.

20   Yang H, Chen H, Gao B, *et al.* Expert panel consensus statement on the applications and precaution strategies of bronchoscopy in patients with COVID-19. *Endosc Ultrasound* 2020; 9: 211–219.

21   Cordovilla R, Alvarez S, Llanos L, *et al.* SEPAR and AEER consensus recommendations on the use of bronchoscopy and airway sampling in patients with suspected or confirmed COVID-19 infection. *Arch Bronconeumol* 2020; 56: Suppl. 2, 19–26.

22   Zhou F, Yu T, Du R, *et al.* Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. *Lancet* 2020; 395: 1054–1062.

23   Colombi D, Villani GD, Maffi G, *et al.* Qualitative and quantitative chest CT parameters as predictors of specific mortality in COVID-19 patients. *Emerg Radiol* 2020; 27: 701–710.

24   Batah SS, Fabro AT. Pulmonary pathology of ARDS in COVID-19: a pathological review for clinicians. *Respir Med* 2021; 176: 106239.

25   Cano EJ, Fuentes XF, Campioli CC, *et al.* Impact of corticosteroids in coronavirus disease 2019 outcomes: systematic review and meta-analysis. *Chest* 2021; 159: 1019–1040.

26   Fox SE, Akmatbekov A, Harbert JL, *et al.* Pulmonary and cardiac pathology in African American patients with COVID-19: an autopsy series from New Orleans. *Lancet Respir Med* 2020; 8: 681–686.

27   Bradley BT, Maioli H, Johnston R, *et al.* Histopathology and ultrastructural findings of fatal COVID-19 infections in Washington State: a case series. *Lancet* 2020; 396: 320–332.

28   Menter T, Haslbauer JD, Nienhold R, *et al.* Postmortem examination of COVID-19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings in lungs and other organs suggesting vascular dysfunction. *Histopathology* 2020; 77: 198–209.